Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Details)

v3.21.2
Stockholders' Equity - Additional Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jan. 01, 2021
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Jun. 09, 2021
Dec. 31, 2020
Nov. 30, 2020
Jun. 30, 2020
Mar. 17, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Common stock, shares authorized   135,000,000   135,000,000   40,000,000 95,000,000      
Common Stock, Increase in authorized shares (in shares)           135,000,000        
Common stock, par or stated value per share   $ 0.0001   $ 0.0001   $ 0.0001 $ 0.0001      
Common stock, shares issued   76,214,398   76,214,398     62,420,439      
Common stock, shares outstanding   76,214,398   76,214,398     62,420,439      
Shelf registration statement, maximum authorized securities               $ 100,000,000    
Percentage of annual equity fee                   2.50%
Issuance of common shares, net of offering costs - At-the-market offering   $ 1,542,000 $ 5,813,000 $ 36,259,000 $ 8,417,000          
Issuance of common shares - Founders Agreement   39,000 $ 731,000 926,000 $ 797,000          
Shelf registration statement remaining authorized securities   58,700,000   58,700,000            
Non-vested Restricted Stock                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Total unrecognized compensation cost related to non-vested   $ 3,100,000   $ 3,100,000            
Weighted average period (in years)       1 year 9 months 18 days            
Performance Shares                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Restricted stock outstanding non-vested   333,334   333,334            
2015 Incentive Plan                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Number of shares available for issuance Authorized                 9,000,000  
Plans expires (in years)       10 years            
Shares are available for issuance   3,319,453   3,319,453            
At the Market Offering                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Number of shares sold       10,860,983            
Sale price per share   $ 3.42   $ 3.42            
Aggregate total gross proceeds from shares sold       $ 37,200,000            
Net proceeds from the offering       $ 36,300,000            
Stock issued during period shares common shares for at the market offering       10,860,983            
Stock issued during period value common shares for at the market offering gross       $ 37,200,000            
Issuance of common shares, net of offering costs - At-the-market offering       36,300,000            
Commissions and other transaction costs       $ 900,000            
Fortress Biotech, Inc                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Number of shares sold 1,742,449     271,515            
Percentage of annual equity fee 2.50% 2.50%   2.50%            
Issuance of common shares - Founders Agreement       $ 926,000            
Agent                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Commission rate   3.00%   3.00%            
Common Class A                    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                    
Common stock, shares authorized           7,000,000        
Common stock, shares issued   7,000,000   7,000,000     7,000,000      
Common stock, shares outstanding   7,000,000   7,000,000     7,000,000